Skip to content

Effects of Combined Spinal Direct Current Stimulation on Upper Limb Recovery in Acquired Brain Injury

Effects of Combined Spinal Direct Current Stimulation on Upper Limb Recovery in Acquired Brain Injury (ABI)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03100370
Enrollment
9
Registered
2017-04-04
Start date
2016-05-31
Completion date
2019-12-17
Last updated
2023-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Brain Injury

Brief summary

This study will compare different polarities of transcutaneous spinal direct current stimulation combined with robotic-assisted arm training (RAT) in adults with acquired brain injury (ABI). Participants will receive 20 minutes of 2.5 milliamps (mA) anodal, cathodal, and sham transpinal direct current stimulation (tsDCS) over cervical spine combined with high intensity robotic-assisted arm training, five days a week, for 2 consecutive weeks.

Detailed description

Acquired brain injury (ABI) is the leading cause of neurological disability in the United States and accounts for the poor physical health and the social dysfunction evident in survivors. Hemiparesis due to acquired brain injury is the primary cause of disability and arm paresis is perceived as the primary cause of disability by individuals who have suffered ABI because of the limitations it creates in performing activities of daily living (ADL). Rehabilitation of the impaired limb is essential for improving motor function after ABI, yet only 31% of ABI survivors receive outpatient rehabilitation. Therefore, effective therapy for upper-limb paresis must be addressed. Approximately 80% of all ABI survivors suffer from upper limb paresis and only 18% of these individuals gain full motor recovery with conventional treatments in the year following ABI. The study will use cross-over, randomized, sham controlled, double-blinded design. Participants with subacute or chronic ABI will each be assigned to receive active anodal spinal stimulation, active cathodal spinal stimulation, and sham spinal stimulation for the same duration, and the order that each participant will receive anodal, cathodal, and sham stimulation will be randomized. In all the experiments participants will receive robotic assisted training for duration of 1.5 hours. The first 20 minutes of training will be coupled with spinal stimulation. Treatment will be administered at an intensity of 5 sessions per week for 2 weeks.

Interventions

DEVICEtsDCS-Anodal Stimulation

2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.

DEVICEtsDCS-Cathodal Stimulation

2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.

DEVICEtsDCS-Sham Stimulation

2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.

DEVICERobotic-assisted training of arm and hand functions

70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

Each participant will receive active anodal spinal stimulation, active cathodal spinal stimulation, and sham spinal stimulation. The order that each participant receives anodal, cathodal, and sham stimulation will be randomized.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Providing written informed consent prior to any study related procedures; 2. Age above 18; 3. Diagnosis of acquired brain injury at least for 6 month 4. No neuropsychiatric comorbidities 5. Not being involved in any specific exercise program (e.g., neuromuscular electrical stimulation (NMES), functional electrical stimulation (FES)) within the previous 3 months; 6. No planned alteration in upper-extremity therapy or medication for muscle tone during the course of the study; 7. Eligibility for standard upper-extremity rehabilitation at the time of enrollment (i.e., absence medical comorbidities that would prevent standard rehabilitation); 8. No condition (e.g., severe arthritis, extreme shoulder pain) that would interfere with valid administration of the measures or with interpreting motor testing; 9. No contraindications to tsDCS: * metal in the head between stimulation area * metal in the spine between stimulation area * implanted brain medical devices 10. No pregnancy; 11. No contraindications for Transcranial Magnetic Stimulation (TMS) and magnetic resonance imaging (MRI) based on TMS and MRI screening forms

Exclusion criteria

1. Uncontrolled epilepsy; 2. Any joint contracture or severe spasticity in the affected upper extremity, as measured by a Modified Ashworth Score \> than 3 out of 4; 3. History of substance abuse; 4. Subject who cannot provide self-transportation to the study location

Design outcomes

Primary

MeasureTime frameDescription
Fugl-Meyer Arm (FMA) Motor ScorebaselineFMA is a stroke-specific, performance based impairment index. It quantitatively measures impairment based on Twitchell and Brunnstrom's concept of sequential stages of motor return in hemiplegic stroke patients. It uses an ordinal scale for scoring of 33 items for the upper limb component of the F-M scale (0:can not perform; 1:can perform partially; 2:can perform fully). Total range is 0-66, 0 being poor and 66 normal.

Secondary

MeasureTime frameDescription
Pinch StrengthBaselineA pinch gauge will be used to measure maximum pinch force.
Quantitative Movement MeasurementChange from baseline at 2 weeks and at 1 monthRobotic movement data will be used to quantitatively measure changes in movement smoothness
Number of Participants With Adverse Effects Related to tsDCSBaselineSafety will be measured by questioning and observing participants at each treatment session. Adverse effects, such as skin redness etc. will be recorded.
Grip StrengthbaselineA grip dynamometer will be used to measure maximum gross grasp force.
Spasticity as Assessed by the Modified Ashworth Scale (MAS)baselineThis test measures spasticity in patients with lesions of the Central Nervous System by testing resistance to passive movement about a joint with varying degrees of velocity. Scores range from 0-4, with 0 indicating normal muscle tone and 4 indicating very high spasticity. The investigators will measure spasticity in the trained upper limb.
Neurophysiologic Testing for Spinal Conductivity (SSEP)Change from baseline at 2 weeks and at 1 month
Change in Strength of Selective Muscle GroupsChange from baseline at 2 weeks and at 1 month
Jebsen Taylor Hand Function Test (JTHFT)BaselineThe JTHFT is a motor performance test and assesses the time needed to perform 7 everyday activities (for example, flipping cards and feeding). Score is reported as items completed per second.
Action Research Arm Test (ARAT)BaselineThe ARAT is used to assess subject's ability to manipulate-lift-release objects horizontally and vertically, which differs in size, weight and shape. The test consists of 19 items divided into 4 sub-tests (grasp, grip, pinch, gross arm movement) and each item is rated on a 4-point scale. The possible total score ranges between 0-57. Higher scores indicate better performance.
Motor Activity Log (MAL)BaselineThe MAL ranges from 0 to 5, with a higher score indicating greater ability to use the affected arm.
Spinal ReflexesChange from baseline at 2 weeks and at 1 month

Countries

United States

Participant flow

Participants by arm

ArmCount
All Study Participants
tsDCS-Anodal Stimulation & robotic-assisted training (RAT) of arm and hand functions: 2.5mA anodal tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device. tsDCS-Cathodal Stimulation & robotic-assisted training (RAT) of arm and hand functions: 2.5mA cathodal tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device. tsDCS-Sham Stimulation & robotic-assisted training (RAT) of arm and hand functions: 2.5mA sham tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device.
9
Total9

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004FG005
First Intervention (2 Weeks)Withdrawal by Subject000100

Baseline characteristics

CharacteristicAll Study Participants
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
2 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
Age, Continuous56.5 years
STANDARD_DEVIATION 6.3
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants
Race/Ethnicity, Customized
Asian
0 Participants
Race/Ethnicity, Customized
Black or African American
3 Participants
Race/Ethnicity, Customized
Hispanic or Latino
4 Participants
Race/Ethnicity, Customized
More than One Race
0 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
0 Participants
Race/Ethnicity, Customized
Unknown or Not Reported
0 Participants
Race/Ethnicity, Customized
White
2 Participants
Region of Enrollment
United States
9 Participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 70 / 7
other
Total, other adverse events
0 / 70 / 70 / 7
serious
Total, serious adverse events
0 / 70 / 70 / 7

Outcome results

Primary

Fugl-Meyer Arm (FMA) Motor Score

FMA is a stroke-specific, performance based impairment index. It quantitatively measures impairment based on Twitchell and Brunnstrom's concept of sequential stages of motor return in hemiplegic stroke patients. It uses an ordinal scale for scoring of 33 items for the upper limb component of the F-M scale (0:can not perform; 1:can perform partially; 2:can perform fully). Total range is 0-66, 0 being poor and 66 normal.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Fugl-Meyer Arm (FMA) Motor Score43.1 score on a scaleStandard Deviation 13.4
tsDCS- Cathodal Stimulation & RATFugl-Meyer Arm (FMA) Motor Score40.6 score on a scaleStandard Deviation 13.4
tsDCS- Sham Stimulation & RATFugl-Meyer Arm (FMA) Motor Score44.2 score on a scaleStandard Deviation 14.1
Primary

Fugl-Meyer Arm (FMA) Motor Score

FMA is a stroke-specific, performance based impairment index. It quantitatively measures impairment based on Twitchell and Brunnstrom's concept of sequential stages of motor return in hemiplegic stroke patients. It uses an ordinal scale for scoring of 33 items for the upper limb component of the F-M scale (0:can not perform; 1:can perform partially; 2:can perform fully). Total range is 0-66, 0 being poor and 66 normal.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Fugl-Meyer Arm (FMA) Motor Score42.4 score on a scaleStandard Deviation 14.7
tsDCS- Cathodal Stimulation & RATFugl-Meyer Arm (FMA) Motor Score42 score on a scaleStandard Deviation 12.3
tsDCS- Sham Stimulation & RATFugl-Meyer Arm (FMA) Motor Score44.4 score on a scaleStandard Deviation 13.5
Primary

Fugl-Meyer Arm (FMA) Motor Score

FMA is a stroke-specific, performance based impairment index. It quantitatively measures impairment based on Twitchell and Brunnstrom's concept of sequential stages of motor return in hemiplegic stroke patients. It uses an ordinal scale for scoring of 33 items for the upper limb component of the F-M scale (0:can not perform; 1:can perform partially; 2:can perform fully). Total range is 0-66, 0 being poor and 66 normal.

Time frame: baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Fugl-Meyer Arm (FMA) Motor Score42 score on a scaleStandard Deviation 13.8
tsDCS- Cathodal Stimulation & RATFugl-Meyer Arm (FMA) Motor Score40 score on a scaleStandard Deviation 12.8
tsDCS- Sham Stimulation & RATFugl-Meyer Arm (FMA) Motor Score42.8 score on a scaleStandard Deviation 12.7
Secondary

Action Research Arm Test (ARAT)

The ARAT is used to assess subject's ability to manipulate-lift-release objects horizontally and vertically, which differs in size, weight and shape. The test consists of 19 items divided into 4 sub-tests (grasp, grip, pinch, gross arm movement) and each item is rated on a 4-point scale. The possible total score ranges between 0-57. Higher scores indicate better performance.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Action Research Arm Test (ARAT)36.7 score on a scaleStandard Deviation 23.6
tsDCS- Cathodal Stimulation & RATAction Research Arm Test (ARAT)34.4 score on a scaleStandard Deviation 21.6
tsDCS- Sham Stimulation & RATAction Research Arm Test (ARAT)40.1 score on a scaleStandard Deviation 22.8
Secondary

Action Research Arm Test (ARAT)

The ARAT is used to assess subject's ability to manipulate-lift-release objects horizontally and vertically, which differs in size, weight and shape. The test consists of 19 items divided into 4 sub-tests (grasp, grip, pinch, gross arm movement) and each item is rated on a 4-point scale. The possible total score ranges between 0-57. Higher scores indicate better performance.

Time frame: Baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Action Research Arm Test (ARAT)35.2 score on a scaleStandard Deviation 22.8
tsDCS- Cathodal Stimulation & RATAction Research Arm Test (ARAT)34 score on a scaleStandard Deviation 21.5
tsDCS- Sham Stimulation & RATAction Research Arm Test (ARAT)37.2 score on a scaleStandard Deviation 23.1
Secondary

Action Research Arm Test (ARAT)

The ARAT is used to assess subject's ability to manipulate-lift-release objects horizontally and vertically, which differs in size, weight and shape. The test consists of 19 items divided into 4 sub-tests (grasp, grip, pinch, gross arm movement) and each item is rated on a 4-point scale. The possible total score ranges between 0-57. Higher scores indicate better performance.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Action Research Arm Test (ARAT)39.5 score on a scaleStandard Deviation 22.7
tsDCS- Cathodal Stimulation & RATAction Research Arm Test (ARAT)35.1 score on a scaleStandard Deviation 22.5
tsDCS- Sham Stimulation & RATAction Research Arm Test (ARAT)39 score on a scaleStandard Deviation 23.6
Secondary

Change in Strength of Selective Muscle Groups

Time frame: Change from baseline at 2 weeks and at 1 month

Population: Data were not collected for this outcome measure

Secondary

Grip Strength

A grip dynamometer will be used to measure maximum gross grasp force.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Grip Strength31.4 kg of forceStandard Deviation 18.7
tsDCS- Cathodal Stimulation & RATGrip Strength22.5 kg of forceStandard Deviation 8.7
tsDCS- Sham Stimulation & RATGrip Strength29.2 kg of forceStandard Deviation 6
Secondary

Grip Strength

A grip dynamometer will be used to measure maximum gross grasp force.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Grip Strength30.1 kg of forceStandard Deviation 19.1
tsDCS- Cathodal Stimulation & RATGrip Strength21.8 kg of forceStandard Deviation 8.6
tsDCS- Sham Stimulation & RATGrip Strength31.8 kg of forceStandard Deviation 15.8
Secondary

Grip Strength

A grip dynamometer will be used to measure maximum gross grasp force.

Time frame: baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Grip Strength27.3 kg of forceStandard Deviation 17
tsDCS- Cathodal Stimulation & RATGrip Strength22.1 kg of forceStandard Deviation 12.5
tsDCS- Sham Stimulation & RATGrip Strength30.1 kg of forceStandard Deviation 18.3
Secondary

Jebsen Taylor Hand Function Test (JTHFT)

The JTHFT is a motor performance test and assesses the time needed to perform 7 everyday activities (for example, flipping cards and feeding). Score is reported as items completed per second.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Jebsen Taylor Hand Function Test (JTHFT).25 activities completed per secondStandard Deviation 0.2
tsDCS- Cathodal Stimulation & RATJebsen Taylor Hand Function Test (JTHFT).18 activities completed per secondStandard Deviation 0.2
tsDCS- Sham Stimulation & RATJebsen Taylor Hand Function Test (JTHFT).26 activities completed per secondStandard Deviation 0.2
Secondary

Jebsen Taylor Hand Function Test (JTHFT)

The JTHFT is a motor performance test and assesses the time needed to perform 7 everyday activities (for example, flipping cards and feeding). Score is reported as items completed per second.

Time frame: Baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Jebsen Taylor Hand Function Test (JTHFT).22 activities completed per secondStandard Deviation 0.2
tsDCS- Cathodal Stimulation & RATJebsen Taylor Hand Function Test (JTHFT).17 activities completed per secondStandard Deviation 0.2
tsDCS- Sham Stimulation & RATJebsen Taylor Hand Function Test (JTHFT).23 activities completed per secondStandard Deviation 0.2
Secondary

Jebsen Taylor Hand Function Test (JTHFT)

The JTHFT is a motor performance test and assesses the time needed to perform 7 everyday activities (for example, flipping cards and feeding). Score is reported as items completed per second.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Jebsen Taylor Hand Function Test (JTHFT).25 activities completed per secondStandard Deviation 0.2
tsDCS- Cathodal Stimulation & RATJebsen Taylor Hand Function Test (JTHFT).2 activities completed per secondStandard Deviation 0.2
tsDCS- Sham Stimulation & RATJebsen Taylor Hand Function Test (JTHFT).22 activities completed per secondStandard Deviation 0.2
Secondary

Motor Activity Log (MAL)

The MAL ranges from 0 to 5, with a higher score indicating greater ability to use the affected arm.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Motor Activity Log (MAL)2.17 score on a scaleStandard Deviation 1.4
tsDCS- Cathodal Stimulation & RATMotor Activity Log (MAL)2.14 score on a scaleStandard Deviation 1.4
tsDCS- Sham Stimulation & RATMotor Activity Log (MAL)2.07 score on a scaleStandard Deviation 1.1
Secondary

Motor Activity Log (MAL)

The MAL ranges from 0 to 5, with a higher score indicating greater ability to use the affected arm.

Time frame: Baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Motor Activity Log (MAL)1.99 score on a scaleStandard Deviation 1.3
tsDCS- Cathodal Stimulation & RATMotor Activity Log (MAL)2.07 score on a scaleStandard Deviation 1.4
tsDCS- Sham Stimulation & RATMotor Activity Log (MAL)2.15 score on a scaleStandard Deviation 1.2
Secondary

Motor Activity Log (MAL)

The MAL ranges from 0 to 5, with a higher score indicating greater ability to use the affected arm.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Motor Activity Log (MAL)2.34 score on a scaleStandard Deviation 1.4
tsDCS- Cathodal Stimulation & RATMotor Activity Log (MAL)1.86 score on a scaleStandard Deviation 1.6
tsDCS- Sham Stimulation & RATMotor Activity Log (MAL)2.2 score on a scaleStandard Deviation 1.4
Secondary

Neurophysiologic Testing for Spinal Conductivity (SSEP)

Time frame: Change from baseline at 2 weeks and at 1 month

Population: Data were not collected for this outcome measure

Secondary

Number of Participants With Adverse Effects Related to tsDCS

Safety will be measured by questioning and observing participants at each treatment session. Adverse effects, such as skin redness etc. will be recorded.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Number of Participants With Adverse Effects Related to tsDCS0 Participants
tsDCS- Cathodal Stimulation & RATNumber of Participants With Adverse Effects Related to tsDCS0 Participants
tsDCS- Sham Stimulation & RATNumber of Participants With Adverse Effects Related to tsDCS0 Participants
Secondary

Number of Participants With Adverse Effects Related to tsDCS

Safety will be measured by questioning and observing participants at each treatment session. Adverse effects, such as skin redness etc. will be recorded.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Number of Participants With Adverse Effects Related to tsDCS0 Participants
tsDCS- Cathodal Stimulation & RATNumber of Participants With Adverse Effects Related to tsDCS0 Participants
tsDCS- Sham Stimulation & RATNumber of Participants With Adverse Effects Related to tsDCS0 Participants
Secondary

Number of Participants With Adverse Effects Related to tsDCS

Safety will be measured by questioning and observing participants at each treatment session. Adverse effects, such as skin redness etc. will be recorded.

Time frame: Baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Number of Participants With Adverse Effects Related to tsDCS0 Participants
tsDCS- Cathodal Stimulation & RATNumber of Participants With Adverse Effects Related to tsDCS0 Participants
tsDCS- Sham Stimulation & RATNumber of Participants With Adverse Effects Related to tsDCS0 Participants
Secondary

Pinch Strength

A pinch gauge will be used to measure maximum pinch force.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Pinch Strength10.4 kg of forceStandard Deviation 4.8
tsDCS- Cathodal Stimulation & RATPinch Strength11.6 kg of forceStandard Deviation 3.6
tsDCS- Sham Stimulation & RATPinch Strength9.5 kg of forceStandard Deviation 3.8
Secondary

Pinch Strength

A pinch gauge will be used to measure maximum pinch force.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Pinch Strength12.1 kg of forceStandard Deviation 5.9
tsDCS- Cathodal Stimulation & RATPinch Strength11.8 kg of forceStandard Deviation 3.9
tsDCS- Sham Stimulation & RATPinch Strength10.9 kg of forceStandard Deviation 4.2
Secondary

Pinch Strength

A pinch gauge will be used to measure maximum pinch force.

Time frame: Baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Pinch Strength11.2 kg of forceStandard Deviation 6.5
tsDCS- Cathodal Stimulation & RATPinch Strength10.92 kg of forceStandard Deviation 11.8
tsDCS- Sham Stimulation & RATPinch Strength9.4 kg of forceStandard Deviation 4.9
Secondary

Quantitative Movement Measurement

Robotic movement data will be used to quantitatively measure changes in movement smoothness

Time frame: Change from baseline at 2 weeks and at 1 month

Population: Data were not collected for this outcome measure

Secondary

Spasticity as Assessed by the Modified Ashworth Scale (MAS)

This test measures spasticity in patients with lesions of the Central Nervous System by testing resistance to passive movement about a joint with varying degrees of velocity. Scores range from 0-4, with 0 indicating normal muscle tone and 4 indicating very high spasticity. The investigators will measure spasticity in the trained upper limb.

Time frame: 2 weeks

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Spasticity as Assessed by the Modified Ashworth Scale (MAS).2 score on a scaleStandard Deviation 0.3
tsDCS- Cathodal Stimulation & RATSpasticity as Assessed by the Modified Ashworth Scale (MAS).3 score on a scaleStandard Deviation 0.2
tsDCS- Sham Stimulation & RATSpasticity as Assessed by the Modified Ashworth Scale (MAS).3 score on a scaleStandard Deviation 0.2
Secondary

Spasticity as Assessed by the Modified Ashworth Scale (MAS)

This test measures spasticity in patients with lesions of the Central Nervous System by testing resistance to passive movement about a joint with varying degrees of velocity. Scores range from 0-4, with 0 indicating normal muscle tone and 4 indicating very high spasticity. The investigators will measure spasticity in the trained upper limb.

Time frame: 1 month

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Spasticity as Assessed by the Modified Ashworth Scale (MAS).05 score on a scaleStandard Deviation 0.09
tsDCS- Cathodal Stimulation & RATSpasticity as Assessed by the Modified Ashworth Scale (MAS).2 score on a scaleStandard Deviation 0.2
tsDCS- Sham Stimulation & RATSpasticity as Assessed by the Modified Ashworth Scale (MAS).3 score on a scaleStandard Deviation 0.3
Secondary

Spasticity as Assessed by the Modified Ashworth Scale (MAS)

This test measures spasticity in patients with lesions of the Central Nervous System by testing resistance to passive movement about a joint with varying degrees of velocity. Scores range from 0-4, with 0 indicating normal muscle tone and 4 indicating very high spasticity. The investigators will measure spasticity in the trained upper limb.

Time frame: baseline

Population: Data were collected for 7 participants in each arm

ArmMeasureValue (MEAN)Dispersion
tsDCS- Anodal Stimulation & Robotic Arm Training (RAT)Spasticity as Assessed by the Modified Ashworth Scale (MAS).2 score on a scaleStandard Deviation 0.2
tsDCS- Cathodal Stimulation & RATSpasticity as Assessed by the Modified Ashworth Scale (MAS).4 score on a scaleStandard Deviation 0.4
tsDCS- Sham Stimulation & RATSpasticity as Assessed by the Modified Ashworth Scale (MAS).3 score on a scaleStandard Deviation 0.3
Secondary

Spinal Reflexes

Time frame: Change from baseline at 2 weeks and at 1 month

Population: Data were not collected for this outcome measure

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026